TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00196339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 5
Description: Cyproterone acetate 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 15
Description: Cyproterone acetate 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 25
Description: Cyproterone acetate 25 mg
Study: NCT01945437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The magnesium group receive intravenous magnesium sulfate.
Study: NCT01529541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg, tablet, once a day (QD)
Study: NCT04433949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy
Description: Undergo LDRT
Study: NCT03669900

Intervention type: PROCEDURE
Group type: OTHER
Intervention: a minimally invasive surgery (SERI)
Description: The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
Study: NCT00157248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dosage used at study start

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dosage used at study start

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dosage used at study start

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dosage used at study start
Study: NCT01308112

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: iron
Description: Daily supplementation with iron (60 mg) as ferrous sulphate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron
Description: Daily supplementation with iron (60 mg) as ferrous sulphate
Study: NCT04101929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 capsule
Description: Patients receive S-1 capsule According to the body surface area \<1.25m2 60mg/d, 1.25 \~ 1.5 m2 80 mg/d, \> 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded.
Study: NCT04247464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Food intake restriction
Study: NCT03702114

Intervention type: DEVICE
Intervention: auricular point detection
Description: This device is only for auricular detection. No additional intervention will be delivered.

Intervention type: DEVICE
Intervention: auricular point detection
Description: This device is only for auricular detection. No additional intervention will be delivered.
Study: NCT02999529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
Study: NCT03382301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin A preconditioning before renal artery stenosis dilation
Description: Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl preconditioning before renal artery stenosis dilation
Description: NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
Study: NCT01424514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 12mg intra nasal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra nasal
Study: NCT01223469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact force assisted irrigated RF ablation
Description: radiofrequency ablation of atrial fibrillation or SVT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact force assisted irrigated RF ablation
Description: radiofrequency ablation of atrial fibrillation or SVT
Study: NCT02533102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: 100 mg tablet administered orally
Study: NCT03178084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID
Description: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz QD + Zidovudine/Lamivudine BID
Description: efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Study: NCT02533102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: 100 mg tablet administered orally
Study: NCT02658006

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: All cardiac surgery procedures
Study: NCT00801281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 1
Description: Prednisone 100 mg p.o. d. 1-5 q. 21 d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 2
Description: Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
Study: NCT02953587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Ghrelin
Description: Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Ghrelin
Description: Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Ghrelin
Description: Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Ghrelin
Description: Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
Study: NCT02951221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074 Treatment A
Description: Lower dose RCF fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074 Treatment B
Description: Lower dose DCF fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074 Treatment C
Description: Higher dose DCF fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074 Treatment D
Description: Higher dose DCF fed
Study: NCT01097421

Intervention type: DRUG
Intervention: Pramipexole Extended Release
Study: NCT05528198

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films without water (A)
Description: Single-dose montelukast sodium oral thin film 5mg under fasted condition without water

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films without water (A)
Description: Single-dose montelukast sodium oral thin film 5mg under fasted condition without water

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films without water (A)
Description: Single-dose montelukast sodium oral thin film 5mg under fasted condition without water

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films with water (B)
Description: Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films with water (B)
Description: Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium oral thin films with water (B)
Description: Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium chewable tablets with water (C)
Description: Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium chewable tablets with water (C)
Description: Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast sodium chewable tablets with water (C)
Description: Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL
Study: NCT00916344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVIA Pacemaker
Description: patient has standard indication for pacemaker therapy
Study: NCT04669951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: uPAR immunohistochemistry
Description: Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
Study: NCT00136435

Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: Induction Phase: Given orally on days 1-28

Intervention type: DRUG
Group type: OTHER
Intervention: doxorubicin
Description: Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle

Intervention type: DRUG
Group type: OTHER
Intervention: vincristine
Description: Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate
Description: Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: asparaginase
Description: Induction: Given into the muscle on day 5

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone
Description: Intensification: Given orally on days 1-5 of each cycle

Intervention type: RADIATION
Group type: OTHER
Intervention: cranial radiation
Description: Given in 10 daily treatments during CNS therapy phase

Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin
Description: Induction: Given intravenously or orally 36 hours after methotrexate

Intervention type: DRUG
Group type: OTHER
Intervention: cytarabine
Description: Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: hydrocortisone
Description: Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: 6-mercaptopurine (6-MP)
Description: CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.

Intervention type: DRUG
Group type: OTHER
Intervention: e. coli L-asparaginase
Description: Intensification: Given in to the muscle weekly.
Study: NCT00972816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1
Description: MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
Study: NCT06451289

Intervention type: DIAGNOSTIC_TEST
Intervention: Head computered tomography
Description: Retrospective data collecting from medical records

Intervention type: DIAGNOSTIC_TEST
Intervention: Head computered tomography
Description: Retrospective data collecting from medical records
Study: NCT03783130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP
Description: Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP
Description: Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP
Description: Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVRGP096-00-VP
Description: Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alum Adjuvant
Description: Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alum Adjuvant
Description: Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alum Adjuvant
Description: Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alum Adjuvant
Description: Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.
Study: NCT01609166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 3% cream application in one side of the body, twice a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream application in the other side of the body, twice a day for 6 months
Study: NCT04085224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: LG Somatropin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: LG Somatropin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: LG Somatropin
Study: NCT00522535

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical repair
Description: Open surgical repair of abdominal aortic aneurysm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent Graft
Description: Endovascular repair of abdominal aortic aneurysm (EVAR)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent Graft
Description: Endovascular repair of abdominal aortic aneurysm (EVAR)
Study: NCT02467257

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: oral ingestion of 30 gram every day for 12 weeks
Study: NCT00373958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent pneumococcal conjugate vaccine
Description: 1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7vPnc pneumococcal conjugate vaccine
Description: 1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
Study: NCT02796859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siltuximab
Description: Investigational agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo
Study: NCT02893176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: macitentan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for macitentan)
Study: NCT02784626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative sedation using dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intraoperative sedation using propofol
Study: NCT01949441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune HDM
Description: Intradermal injection 1 x 4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection 1 x 4 administrations 4 weeks apart